Guangzhou Wondfo Biotech Co.,ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Guangzhou Wanfu Biotechnology Co., Ltd. (hereinafter referred to as Wanfu Biotechnology) was established in 1992, headquartered in Guangzhou Science City. Currently, it employs about 3000 people and was listed on the Growth Enterprise Board of the Shenzhen Stock Exchange on June 30, 2015, becoming the first domestic POCT stock. The business field of Wanfu Biotechnology belongs to the in vitro diagnostic industry under the medical device industry. We specialize in the research and development, manufacturing, marketing, and service of rapid diagnostic reagents and supporting instruments, and are one of the leading enterprises in POCT in China. Our products are sold to over 140 countries and regions worldwide, and are widely used in fields such as clinical testing, critical care, grassroots healthcare, epidemic monitoring, disaster relief, on-site law enforcement, and family personal health management. Wanfu Biotechnology has successively won the titles of National Torch Program Key High tech Enterprise, National Biotechnology High tech Industrialization Demonstration Base, National Intellectual Property Advantage Enterprise, World Health Organization PQ Certification Enterprise, and World Customs Organization AEO Advanced Certification Enterprise. It is one of the first in vitro diagnostic reagent enterprises in China to pass on-site FDA audits, and has established the only national engineering laboratory in the POCT field. After nearly thirty years of development, the company has built a relatively complete technology platform and product line, making it the enterprise with the most technology platform layout and the richest product line among domestic POCT enterprises. The company currently has immune colloidal gold technology platform, immune fluorescence technology platform, electrochemical technology platform, dry biochemical technology platform, chemiluminescence technology platform, molecular diagnosis technology platform, pathological diagnosis technology platform, as well as instrument technology platform and biological raw material platform. Based on the above nine technology platforms, it has formed cardiovascular and cerebrovascular diseases, inflammation, tumors, infectious diseases, and drug testing (drug abuse) We have a rich product line in the field of eugenics and childcare testing, with products sold to over 140 countries and regions worldwide. Our products are widely used in clinical testing, critical care, grassroots medical care, epidemic monitoring, disaster relief, on-site law enforcement, and family personal health management. As of June 30, 2020, the company has obtained a total of 476 product registration certificates such as NMPA, FDA, CE, and Canadian MDALL, ranking among the top in the industry. The company adheres to the concept of "united front" and builds the "Wanfu ecosystem". Open up the upstream and downstream of the industrial chain through outward mergers and acquisitions, and improve the layout of products, technologies, and channels; Simultaneously activating organizations through internal entrepreneurship and incubation, expanding product and business interfaces, and enhancing the company's vitality. As of December 31, 2019, the company has initially formed a "Wanfu ecosystem" of "strengthening downstream markets and channels, and deploying upstream products and technologies"; The company has invested in Atlas Genetics in the UK, iCubate in the US, and Biocartis in Belgium, and has established strategic cooperation through joint ventures to promote technology and product introduction, achieving a layout in the field of molecular diagnosis. Through the organic interaction and strategic collaboration of various entities in the "Wanfu Ecosphere", the company's business interface has rapidly expanded, operational efficiency continues to improve, and promotes rapid and stable growth of the company's performance. In order to integrate global research and innovation capabilities, Wanfu Biotechnology has established research and development centers in cities such as San Diego in the United States and Guangzhou in China, with over 530 first-class researchers at home and abroad; Promote a globalized intelligent manufacturing system, invest and establish factories in Asia, South America, Africa, and the Commonwealth of Independent States; At the same time, we have a global marketing service network with over 20 domestic and foreign subsidiaries, providing product solutions and technical support to customers in over 140 countries and regions worldwide. As one of the leading enterprises in POCT in China, one of the core concepts of Wanfu Biotechnology is "not letting life wait". In a simple sentence, it not only explains Wanfu Biological's original intention to provide technology and products for public health, but also reflects the universal love of the enterprise. It is precisely because of this empathy that Wanfu Biotechnology has always regarded "providing professional and fast diagnosis and chronic disease management product services, pursuing a friendly and convenient user experience, improving the quality of life and health, and realizing the common dreams of employees, customers, and partners" as the direction of enterprise development. We constantly strive for excellence, protect every health, and "serve Wanzhong and trust Wanfu" deeply into the hearts of every Wanfu person, inspiring them to move forward. The company adheres to the core concept of "serving the masses, believing in the future" and the core value system of "one point, two lines, three joys, and four ones". One of them is the viewpoint of "putting practice first". The 'second line' refers to 'adhering to the mass line internally; adhering to the united front externally'. The 'three joys' refer to' customers like it, employees like it, and partners like it '.April 1st "is" we strive passionately and move every customer; we respect and tolerate, grow every employee; we dare to win and enjoy, achieve every partner; we pursue excellence, and safeguard every piece of health ". |
| Headquarter | Guangzhou |
| Establish Date | 11/13/1992 |
| Listed Code | 300482.SZ |
| Listed Date | 6/30/2015 |
| Chairman | Wang Jihua. |
| CEO | Peng Zhongxiong. |
| Website | www.wondfo.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
